Antileukotrienes in clinical development for asthma

Expert Opinion on Investigational Drugs

Volumn 11, Issue 1, 2002, Pages 49-58

  Centanni, S ^a   Santus, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antileukotrienes; Asthma therapy; Clinical efficacy; Clinical use; Compliance; Leukotrienes; Safety

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; A 64007; ACETYLSALICYLIC ACID; ANTIGEN; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE INHIBITOR; ARACHIDONIC ACID; BAY 1005; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CI 204219; CIANLUKAST; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE C4; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; NEDOCROMIL; POBILUKAST; PRANLUKAST; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; SALBUTAMOL; SALM COMBO; TOMELUKAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ADOLESCENT; ADULT; ALLERGY; ASTHMA; CHILD; CHRONIC INFLAMMATION; CONSULTATION; CONTROLLED STUDY; DETERIORATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EXERCISE INDUCED ASTHMA; HUMAN; LONG TERM CARE; MEDIATOR; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; SIDE EFFECT;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES;

EID: 0036139849     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.1.49     Document Type: Review

References (104)

1. The role of leukotrienes in inflammation
2. Leukotrienes as mediators of airway obstruction and inflammation in asthma
3. Diversity of group types, regulation and function of phospholipases A2
4. Prostaglandins and thromboxane
5. 5-Lipoxigenase
6. Arachidonate 15-lipoxigenase
7. Blood eosinophil leukotriene C4 production in asthma of different severities
8. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases
9. Elevated levels of leukotriene C4 in bronchoalveolar lavage flid from atopic asthmatics after endobronchial allergen challenge
10. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma
11. Recovery of leukotriene E4 from the urine of patients with airway obstruction
12. Leukotrienes are potent constrictors of human bronchi
13. Slow-reacting substance, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro
14. Airway responsiveness to leukotrienes C4 and D4 and to methacoline in patients with asthma and normal controls
15. Leukotrienes C4, D4 and E4 enhance histamine responsiveness in asthmatic airways
16. Leukotriene E4 and granulocytic infiltration into asthmatic airways
17. Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis
18. Cysteinyl leukotrienes enhance growth of human airway epithelial cells
19. The mechanism of action of corticosteroids in asthma
20. Chemokinetic activity for arachidonic acid lipoxygenase products on leukocytes of different species
21. Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils and other lipoxygenase products
22. Selective transduction of human polymorphonuclear leukocyte functions by subsets of receptors for leukotriene B4
23. Leukotriene B4 action of endothelium mediates augmented neutrophil/endothelial adhesion
24. Persistant airway eosinophilia after leukotriene D4 administration in conscious guinea-pigs: Modulation by a peptidoleukotriene antagonist and interleukin (IL-5) monoclonal antibody
25. IL-5 increases expression of 5-lipoxygenase protein and translocates 5-lipoxygenase to the nucleus in human blod eosinophils
26. Biosynthesis of cysteinyl-leucotrienes in aspirin-intollerant asthma
27. Allergen-induced release of sulphidapeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis
28. Behaviour and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis
29. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist
30. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma; a multicenter, randomized, double-blind trial
31. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial
32. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist
33. Bay u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes
34. Characterization of the human cysteinyl leukotriene CysLT1 receptor
35. Prostanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature
36. A second cysteinyl leukotriene receptor in human lung
37. Cysteinyl-leukotriene receptors in pulmonary vessels
38. Characterization of the human cysteinyl leukotriene 2 receptor
39. The potential role of tocopherol in asthma and allergy. Modification of the leukotriene pathway
40. Urinary leukotriene E4 after exercise challenge in children with asthma
41. Role of leukotrienes in exercise-induced asthma: Inibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist
42. Increased urinary excretion of LTE4 after exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
43. Increased excretion of leukotriene E4 during aspirin-induced asthma
44. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatic subjects
45. Acute and chronic effects of a 5-lipoxigenase inhibitor in asthma: A 6-month randomised multicenter trial
46. Pranlukast (Ultair TM) is effective in improving asthma: Results of a 12-week, multicenter, dose ranging study
47. Effect of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma
48. Efficacy and safety of zafirlukast (Accolate) in patients with mild to moderate asthma
49. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma- a randomised double-blind, placebo-controlled trial
50. Evaluation of the effects of zafirlukast 40 mg bid in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: Preliminary data
51. Effect of zafirlukast on Ciliary Beat Frequency (CBF) in stable mild asthmatic allergic subjects
52. Biosynthesis of cysteinyl-leucotrienes in aspirin-intollerant asthma
53. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma
54. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast
55. Parent and child preference for montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in asthmatic children ages 6 to 11
56. Montelukast (MK-0476), a cysLT1 receptor antagonist, improves asthma outcomes over a 3-month treatment period
57. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 years
58. Pranlukast (UltairTM) improves FEV1 in patients with asthma: Results of 12-week multicenter study vs Nedocromil
59. Effects of 13 weeks of treatment with ICI 204,219 (AccolateTM) or cromolyn sodium (IntalTM) in patients with mild to moderate asthma
60. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
61. Effect of AccolateTM (Zafirlukast; 20 mg BD) in permitting reduced therapy with inhaled steroids: A multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day
62. Leukotriene-receptor antagonist
63. Therapeutic advances: Leukotriene antagonist for the treatment of asthma
64. Comparison of fluticasone proprionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta-2 agonist alone
65. Fluticasone proprionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus motelukast
66. Benefit from adding the 5-lipoxygenase inhibithor zileuton to conventional therapy in aspirin-intollerant asthmatics
67. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
68. Intolerance to aspirin: Clinical stusies and consideration of its pathogenesis
69. Diagnosis, prevention and treatment of adverse reactions to aspirin and non steroidal anti-inflammatorydrugs
70. Mechanism of aspirin-induced asthma
71. The role of leukotrienes in asthma and allergic rhinitis
72. Urinary leukotriene E4 in bronchial asthma
73. Release of peptide leukotriene into vasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients
74. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics
75. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects
76. Montelukast (MK-0476), a cysLT1 receptor antagonist, improves asthma control in aspirin-intollerant asthmatic patients
77. The Swedish-Polish treatment study with the 5-lipoxygenase inhibitor Zileuton in aspirin-intollerant asthmatics
78. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma
79. Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids
80. Exercise-induced asthma
81. Urinary leukotriene E4 after exercise challenge in children with asthma
82. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxigenase inhibitor
83. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist
84. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma
85. Airway responsiveness: Standardized challengetesting with pharmacological, physical and sensitizing stimuli in adults
86. New treatments for Exercise-Induced Asthma
87. Montelukast for mild and exercise-induced asthma
88. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children
89. Comparative effects of long-acting beta2-agonists, leukotriene reeceptor antagonists, and a 5-lipoxigenase inhibitor on exercise-induced asthma
90. Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast
91. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma
92. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma
93. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma
94. Leukotriene antagonist and Churg-Strauss syndrome: The smoking gun
95. Churg-Strauss syndrome associated with zafirlukast
96. Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast
97. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment
98. Difficult asthma or Churg-Strauss syndrome?
99. Montelukast product monograph
100. United airways disease: Therapeutic aspects